AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Reflux Esophagitis Phase III Study (Maintenance Treatment)
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2010-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 540
- Registration Number
- NCT00634114
- Locations
- 🇯🇵
Research Site, Tottori, Japan
IRESSA™ (Gefitinib) in Breast Cancer Patients
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00632723
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
Phase 4
Completed
- Conditions
- Type IIa and IIb Hypercholesterolaemia
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 668
- Registration Number
- NCT00631189
- Locations
- 🇫🇷
Research Site, Yffiniac, France
Prevention of Gastric Ulcers
Phase 3
Completed
- Conditions
- NSAID Associated Gastric Ulcers
- Interventions
- Drug: PlaceboDrug: Esomeprazole
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 504
- Registration Number
- NCT00629512
An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00629564
Ulcer Prevention II
Phase 3
Completed
- Conditions
- NSAID Associated Gastric Ulcers
- Interventions
- Drug: EsomeprazoleDrug: Placebo
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT00629928
Adult Asthmatics and Acid Reflux
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1400
- Registration Number
- NCT00628953
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Drug: PlaceboDrug: Esomeprazole
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00628342
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 97
- Registration Number
- NCT00628251
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: beta-II-agonist, inhale steroidDrug: Symbicort TBH - Turbuhaler
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2012-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 430
- Registration Number
- NCT00628758
- Locations
- 🇹🇷
Research Site, Zonguldak, Turkey
© Copyright 2025. All Rights Reserved by MedPath